

InnerOptic's 3D guidance system is a "GPS" that improves physician accuracy and reduces procedure times.


Company Profile

With a mission of "*Simpler, Safer Surgery through 3D Visualization Technology*," InnerOptic is revolutionizing minimally invasive surgery (MIS) with its advanced visualization products.

InnerOptic Technology was launched in 2003 to commercialize breakthrough medical visualization technology developed at the University of North Carolina-Chapel Hill. InnerOptic has an exclusive license to UNC's patents in minimally invasive surgery, medical visualization and image-guided surgery. InnerOptic has extended this technology with its own patent-pending innovations. Located near Research Triangle Park, NC, InnerOptic has close relationships with industry pioneers from medical teams at CMC and UNC, and access to their state-of-the-art medical facilities.

InVision™ System (IVS)

InnerOptic's innovative InVision™ System provides a "*GPS for needle guidance*," enhancing the surgeon's or interventional radiologist's ability to use ultrasound for accurate needle placement. Like a GPS, IVS continually monitors the positions of the surgical devices in 3D and presents the physician with an integrated, intuitive computer-enhanced display *in real time*, resulting in a faster and safer procedure. The InVision System (IVS) addresses the spatial coordination problem inherent with using ultrasonic imagery for needle guidance. Physicians can perform biopsies and ablations faster, more accurately and with greater confidence when using the InVision System.



InVision Provides Needle Guidance for Tumor Ablations.

The InVision System renders the 3D position of the needle, ultrasound image, ablation volume, and needle trajectory on a stereoscopic display.

Improved surgeon performance has been demonstrated in multiple studies and IVS has been enthusiastically endorsed by top liver surgeons.

IVS is available today for trials and demonstrations and expects to receive FDA clearance in the Spring, 2009. IVS is indicated for "*enhancing the ultrasonic image of an interventional needle or needle-like rigid device, such as a biopsy needle, an aspiration needle, or ablation needle, and for predicting its future path on a stereoscopic computer monitor screen.*"

The Target Market

Despite its enormous popularity, minimally invasive surgery is inherently more difficult to perform than open surgery, and is *the leading cause for malpractice claims against general surgeons*. While existing imaging modalities (CT, MRI, ultrasound) provide basic guidance, there is no product today that provides intuitive, 3D stereoscopic, real-time guidance for soft-tissue needle-based interventions. InnerOptic fills this void, targeting the following “soft-tissue” interventions.

Soft-Tissue Procedure	# Procedures
Breast Biopsies and Ablations	1,000,000
Gall Bladder Removal (Cholecystectomy)	750,000
Liver Tumor Ablation	28,000
Prostrate Tumor Treatment	155,000
Pancreatic Tumor Treatment	5,000
Uterine Fibroid Removal (Myomectomy)	18,000
Colon Tumor Treatment (Colectomy)	9,000
Total	1,965,000

U.S. Soft-Tissue MIS Market (Dept of Health & Human Services, 2005)

IVS supports any needle-based intervention using ultrasonic guidance, including percutaneous, open and laparoscopic interventions.

Management Team

Brian Heaney, CEO. Successful Silicon Valley entrepreneur with 25+ years industry experience. GE Medical, Apple Computer, Bytemobile, and Liberate Technologies. MS, Duke.

David Iannitti, MD, FACS, Chief Medical Officer. Chief of Hepatopancreaticobiliary Surgery, Carolinas Medical Center. Leading researcher in tumor ablation.

Kurtis Keller, Co-Founder and COO. UNC medical researcher for 15 years. MS, NCSU.

Sharif Razzaque, PhD, CTO. Expert in medical visualization and computer interfaces. PhD, UNC.

Medical Advisory Board


Henry Fuchs, PhD, Co-Founder. World-renowned pioneer in 3D graphics and medical Augmented Reality. Professor of Computer Science and an Adjunct Professor Biomedical Engineering at UNC.

Allan Siperstein, MD. Head of Endocrine Surgery, Cleveland Clinic Foundation. Leading researcher in laparoscopic surgery and liver tumor ablation with extensive publications in peer-reviewed medical journals.

Anthony A. Meyer, MD, PhD. Chairman of the Department of Surgery at UNC Hospitals. Over 200 publications in professional journals.

Paul Hansen, MD, FACS. Director of the MIS and Liver Cancer Surgery, Oregon Clinic. Leading liver and pancreatic surgeon.

John Martinie, MD, FACS. Hepatopancreaticobiliary surgeon and faculty member, Carolinas Medical Center. Expert on the daVinci robot and has published many research studies related to hepatic and colorectal disease.



In Vision Displays Ultrasound Image, Needle and ablation volume guide in 3D Stereo.

IVS renders the ultrasound image, needle and needle trajectory in 3D, while optionally displaying an ablation volume guide (wireframe cage).